The Reproductive Outcome of Women with Hypogonadotropic Hypogonadism in IVF.
anovulation
cumulative live birth rate
hypogonadotropic hypogonadism
in vitro fertilization and embryo transfer
infertility
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
01
2022
accepted:
04
05
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
The purpose of this study was to evaluate the reproductive outcome of patients with hypogonadotropic hypogonadism (HH) receiving The reproductive outcome of 81 HH patients and 112 controls who underwent oocyte retrieval was evaluated retrospectively in the Center for Reproductive Medicine of Peking University Third Hospital from 2010 to 2019. The basic levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), androstenedione (A) and prolactin (PRL) were significantly lower in the HH group than the control group. Although the HH patients required a significantly longer stimulation and higher gonadotropin (Gn) doses than the control patients, the total number of oocytes retrieved, fertilized embryos, two pronuclear (2PN) embryos, transferable embryos, fertilization and 2PN rates were comparable between the two groups. Although the live birth rate (LBR) of the first fresh cycle was higher in the control group than the HH group, there was no statistical significance. Then we further divided HH patients into two subgroups according to the etiology. Forty-one cases were termed as congenital HH (CHH), while the other 40 cases were termed as acquired HH (AHH), the latter includes functional hypothalamic amenorrhea (FHA) and pituitary HH (PHH). Our results showed that there were no significant differences in basic clinical characteristics and IVF parameters between the two groups. In the HH group, a total of 119 oocyte retrieval cycles were carried out and they responded adequately to ovulation induction. Urinary human menopausal gonadotropin (HMG) was used alone in 90 cycles while combination of HMG and recombinant human follicle stimulating hormone (rFSH) in the other 29 cycles. There were no significant differences in IVF-related parameters between the two groups. The conservative cumulative live birth rates (CLBRs) after the first, the second and ≥third cycles were 43.21%, 58.02% and 60.49%, respectively, while the corresponding optimal CLBRs were 43.21%, 68.45% and 74.19%. The preterm birth (PTB) rates of singletons and twin pregnancy in HH patients were 8.33% (3/36) and 30.77% (4/13), respectively. IVF-ET is an effective treatment for HH patients with infertility and patients can get satisfactory pregnancy outcomes.
Identifiants
pubmed: 35733765
doi: 10.3389/fendo.2022.850126
pmc: PMC9208655
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
850126Informations de copyright
Copyright © 2022 Zhang, Zhang, Yang, Chen, Liu, Li, Qiao and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gynecol Endocrinol. 2016 Sep;32(9):728-732
pubmed: 26984343
Can J Psychiatry. 1983 Dec;28(8):624-8
pubmed: 6420035
Eur J Endocrinol. 2007 Aug;157 Suppl 1:S3-14
pubmed: 17785694
N Engl J Med. 2011 Jan 20;364(3):215-25
pubmed: 21247312
J Clin Endocrinol Metab. 2014 Jun;99(6):E1045-9
pubmed: 24635131
J Biomed Res. 2020 Aug 14;34(5):361-368
pubmed: 32981896
Fertil Steril. 2013 Feb;99(2):393-9
pubmed: 23141053
Hum Reprod. 2016 Jan;31(1):93-9
pubmed: 26537922
Arch Gynecol Obstet. 2022 Jan;305(1):251-259
pubmed: 34350510
N Engl J Med. 2009 Jan 15;360(3):236-43
pubmed: 19144939
Int J Mol Sci. 2021 Aug 30;22(17):
pubmed: 34502334
Ann Saudi Med. 2013 May-Jun;33(3):235-40
pubmed: 23793424
Hum Reprod. 2005 Jan;20(1):101-7
pubmed: 15513979
Clin Exp Obstet Gynecol. 2010;37(2):120-2
pubmed: 21077502
Gynecol Endocrinol. 2010 Sep;26(9):652-7
pubmed: 20504098
Fertil Steril. 2008 Aug;90(2):395-400
pubmed: 17919608
Hum Reprod. 1995 Jun;10(6):1549-53
pubmed: 7593533
Hum Genet. 2021 Jan;140(1):77-111
pubmed: 32200437
Hum Fertil (Camb). 2021 Nov 9;:1-10
pubmed: 34753367
Ultrasound Obstet Gynecol. 2018 Jan;51(1):43-53
pubmed: 29114987
J Clin Endocrinol Metab. 2011 Dec;96(12):3609-14
pubmed: 21937624
Nat Rev Endocrinol. 2015 Sep;11(9):547-64
pubmed: 26194704
Sports Med. 1998 Jun;25(6):369-406
pubmed: 9680659
Hum Reprod. 2004 Nov;19(11):2442-4
pubmed: 15358719
J Assist Reprod Genet. 2005 Apr;22(4):167-71
pubmed: 16021861
J Clin Invest. 2010 Oct;120(10):3668-72
pubmed: 20940512
Syst Biol Reprod Med. 2015;61(4):228-32
pubmed: 26042899
Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):29-32
pubmed: 22884795